RxDoctor Payments Data

Nazneen Tata, MD

Interventional Cardiology · Hot Springs, ARNPI 1770891970

Payments from drug & device makers

$2,310in general payments, 2019–2025

Across 88 payments — averaging $26.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Novartis$413
  • Amgen$134
  • Irhythm Technologies, Inc.$118
  • E.r. Squibb & Sons, L.L.C.$116
  • Boston Scientific$83
  • plus $408 from 11 others

What the payments were for

  • Travel & lodging$91640%
  • Food & beverage$1,38160%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,310 in reported general payments places this provider in the 15th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$187,904
Medicare patients
939
Services billed
2,629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban175$159,653
XareltoRivaroxaban93$72,607
EntrestoSacubitril/Valsartan78$61,468
BrilintaTicagrelor24$19,491
FarxigaDapagliflozin Propanediol19$10,886
Repatha SureclickEvolocumab12$6,639
Metoprolol Succinate181$2,163
Atorvastatin Calcium283$2,035
Ezetimibe173$1,949
Amiodarone Hcl32$1,325
Clonidine11$1,247
Ranolazine ErRanolazine11$1,220
Carvedilol175$1,063
ClopidogrelClopidogrel Bisulfate102$974
Propafenone Hcl22$806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$159,653175 claims
Johnson & JohnsonXarelto$56$72,60793 claims
NovartisEntresto$413$61,46878 claims
AstraZenecaBrilinta, Farxiga$30$30,37743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 89 interventional cardiology providers in Arkansas.

Other interventional cardiology in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →